 The FDA has granted Orphan Drug Designation to RegenXbio Incs NASDAQ: RGNX RGX-202, potential one-time gene therapy for Duchenne muscular dystrophy Duchenne. Duchenne is a genetic disorder characterized by progressive muscle degeneration and weakness due to the alterations of a protein called dystrophin that helps keep muscle cells intact. 